Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia
: Persistent infection of cervical epithelium with “high risk” human papillomavirus (HPV) results in cervical intraepithelial neoplasia (CIN) from which squamous cancer of the cervix can arise. A study was undertaken to evaluate the safety and immunogenicity of an HPV16 immunotherapeutic consisting...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2004-11, Vol.23 (2), p.172-181 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 181 |
|---|---|
| container_issue | 2 |
| container_start_page | 172 |
| container_title | Vaccine |
| container_volume | 23 |
| creator | Frazer, Ian H. Quinn, Michael Nicklin, Jim L. Tan, Jeffrey Perrin, Lew C. Ng, Peng O’Connor, Vivienne M. White, Olivia Wendt, Ngaire Martin, Juliet Crowley, Jayne M. Edwards, Stirling J. McKenzie, Andrew W. Mitchell, Susan V. Maher, Darryl W. Pearse, Martin J. Basser, Russell L. |
| description | : Persistent infection of cervical epithelium with “high risk” human papillomavirus (HPV) results in cervical intraepithelial neoplasia (CIN) from which squamous cancer of the cervix can arise. A study was undertaken to evaluate the safety and immunogenicity of an HPV16 immunotherapeutic consisting of a mixture of HPV16 E6E7 fusion protein and ISCOMATRIX™ adjuvant (HPV16 Immunotherapeutic) for patients with CIN.
: Patients with CIN (
n = 31) were recruited to a randomised blinded placebo controlled dose ranging study of immunotherapy.
: Immunotherapy was well tolerated. Immunised subjects developed HPV16 E6E7 specific immunity. Antibody, delayed type hypersensitivity, in vitro cytokine release, and CD8 T cell responses to E6 and E7 proteins were each significantly greater in the immunised subjects than in placebo recipients. Loss of HPV16 DNA from the cervix was observed in some vaccine and placebo recipients.
: The HPV16 Immunotherapeutic comprising HPV16E6E7 fusion protein and ISCOMATRIX™ adjuvant is safe and induces vaccine antigen specific cell mediated immunity. |
| doi_str_mv | 10.1016/j.vaccine.2004.05.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67059467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X04004189</els_id><sourcerecordid>67059467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-98be62b263063e34164721b5b41d95c941de623c9eb53fdd0490fed8912a5283</originalsourceid><addsrcrecordid>eNqFkdGK1DAUhoMo7jj6CEpA9K41aZO0uZJlGN2BlV10kL0LaXrKpLRpTdpZ5t4n8BF8NJ_ELFNY8Mark5zzncM5_4_Qa0pSSqj40KZHbYx1kGaEsJTwlND8CVrRssiTjNPyKVqRTLCEUXJ3gV6E0BJCeE7lc3RBeXyQnK3Qr9uDDoApDtNcn_DQ4Kvb71QkYQRjG2uw7fvZDdMBvB5P-N5OB7wV2wI3c7CDw6MfJrAOa1fj3bfNzZfL_dfd3Z-fv7Gu2_mo3YRj9X7owZ2bDfijNbqL6clrGGMOOhv_Doax08Hql-hZo7sAr5a4RvtP2_3mKrm--bzbXF4nhlE5JbKsQGRVJnIicsgZFazIaMUrRmvJjYwh1nMjoeJ5U9eESdJAXUqaaZ6V-Rq9P4-NJ_yYIUyqt8FA1-m4yRyUKAiXTBQRfPsP2A6zd3E1FXWURBAe5VwjfqaMH0Lw0KjR2177k6JEPTimWrU4ph4cU4Sr6Fjse7NMn6se6seuxaIIvFsAHaJujdfO2PDICUYpZTJyH88cRM2OFrwKxoIzUFsPZlL1YP-zyl9Llrc-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559060555</pqid></control><display><type>article</type><title>Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Frazer, Ian H. ; Quinn, Michael ; Nicklin, Jim L. ; Tan, Jeffrey ; Perrin, Lew C. ; Ng, Peng ; O’Connor, Vivienne M. ; White, Olivia ; Wendt, Ngaire ; Martin, Juliet ; Crowley, Jayne M. ; Edwards, Stirling J. ; McKenzie, Andrew W. ; Mitchell, Susan V. ; Maher, Darryl W. ; Pearse, Martin J. ; Basser, Russell L.</creator><creatorcontrib>Frazer, Ian H. ; Quinn, Michael ; Nicklin, Jim L. ; Tan, Jeffrey ; Perrin, Lew C. ; Ng, Peng ; O’Connor, Vivienne M. ; White, Olivia ; Wendt, Ngaire ; Martin, Juliet ; Crowley, Jayne M. ; Edwards, Stirling J. ; McKenzie, Andrew W. ; Mitchell, Susan V. ; Maher, Darryl W. ; Pearse, Martin J. ; Basser, Russell L.</creatorcontrib><description>: Persistent infection of cervical epithelium with “high risk” human papillomavirus (HPV) results in cervical intraepithelial neoplasia (CIN) from which squamous cancer of the cervix can arise. A study was undertaken to evaluate the safety and immunogenicity of an HPV16 immunotherapeutic consisting of a mixture of HPV16 E6E7 fusion protein and ISCOMATRIX™ adjuvant (HPV16 Immunotherapeutic) for patients with CIN.
: Patients with CIN (
n = 31) were recruited to a randomised blinded placebo controlled dose ranging study of immunotherapy.
: Immunotherapy was well tolerated. Immunised subjects developed HPV16 E6E7 specific immunity. Antibody, delayed type hypersensitivity, in vitro cytokine release, and CD8 T cell responses to E6 and E7 proteins were each significantly greater in the immunised subjects than in placebo recipients. Loss of HPV16 DNA from the cervix was observed in some vaccine and placebo recipients.
: The HPV16 Immunotherapeutic comprising HPV16E6E7 fusion protein and ISCOMATRIX™ adjuvant is safe and induces vaccine antigen specific cell mediated immunity.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2004.05.013</identifier><identifier>PMID: 15531034</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adjuvants, Immunologic ; Adolescent ; Adult ; Applied microbiology ; Biological and medical sciences ; Cancer Vaccines - immunology ; Cancer Vaccines - therapeutic use ; Cellular immunity ; Cervical cancer ; Cervical intraepithelial neoplasia ; Cervical Intraepithelial Neoplasia - immunology ; Cervical Intraepithelial Neoplasia - therapy ; Cervical Intraepithelial Neoplasia - virology ; Cholesterol - therapeutic use ; Delayed type hypersensitivity ; Drug Combinations ; Experimental design ; Female ; Fundamental and applied biological sciences. Psychology ; Histology ; Human papillomavirus ; Humans ; Hypersensitivity ; Immunization ; Immunogenicity ; Immunotherapy ; Infections ; Laboratories ; Lymphocytes ; Medical sciences ; Microbiology ; Middle Aged ; Miscellaneous ; Oncogene Proteins, Viral - genetics ; Papillomaviridae - immunology ; Papillomavirus E7 Proteins ; Papillomavirus Infections - immunology ; Papillomavirus Infections - therapy ; Papillomavirus Infections - virology ; Patients ; Phospholipids - therapeutic use ; Proteins ; Recombinant Fusion Proteins - immunology ; Recombinant Fusion Proteins - therapeutic use ; Repressor Proteins - genetics ; Saponins - therapeutic use ; Tumors ; Uterine Cervical Dysplasia - immunology ; Uterine Cervical Dysplasia - therapy ; Uterine Cervical Dysplasia - virology ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Viral load ; Virology</subject><ispartof>Vaccine, 2004-11, Vol.23 (2), p.172-181</ispartof><rights>2004 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Elsevier Limited Nov 25, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-98be62b263063e34164721b5b41d95c941de623c9eb53fdd0490fed8912a5283</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X04004189$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16411149$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15531034$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frazer, Ian H.</creatorcontrib><creatorcontrib>Quinn, Michael</creatorcontrib><creatorcontrib>Nicklin, Jim L.</creatorcontrib><creatorcontrib>Tan, Jeffrey</creatorcontrib><creatorcontrib>Perrin, Lew C.</creatorcontrib><creatorcontrib>Ng, Peng</creatorcontrib><creatorcontrib>O’Connor, Vivienne M.</creatorcontrib><creatorcontrib>White, Olivia</creatorcontrib><creatorcontrib>Wendt, Ngaire</creatorcontrib><creatorcontrib>Martin, Juliet</creatorcontrib><creatorcontrib>Crowley, Jayne M.</creatorcontrib><creatorcontrib>Edwards, Stirling J.</creatorcontrib><creatorcontrib>McKenzie, Andrew W.</creatorcontrib><creatorcontrib>Mitchell, Susan V.</creatorcontrib><creatorcontrib>Maher, Darryl W.</creatorcontrib><creatorcontrib>Pearse, Martin J.</creatorcontrib><creatorcontrib>Basser, Russell L.</creatorcontrib><title>Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>: Persistent infection of cervical epithelium with “high risk” human papillomavirus (HPV) results in cervical intraepithelial neoplasia (CIN) from which squamous cancer of the cervix can arise. A study was undertaken to evaluate the safety and immunogenicity of an HPV16 immunotherapeutic consisting of a mixture of HPV16 E6E7 fusion protein and ISCOMATRIX™ adjuvant (HPV16 Immunotherapeutic) for patients with CIN.
: Patients with CIN (
n = 31) were recruited to a randomised blinded placebo controlled dose ranging study of immunotherapy.
: Immunotherapy was well tolerated. Immunised subjects developed HPV16 E6E7 specific immunity. Antibody, delayed type hypersensitivity, in vitro cytokine release, and CD8 T cell responses to E6 and E7 proteins were each significantly greater in the immunised subjects than in placebo recipients. Loss of HPV16 DNA from the cervix was observed in some vaccine and placebo recipients.
: The HPV16 Immunotherapeutic comprising HPV16E6E7 fusion protein and ISCOMATRIX™ adjuvant is safe and induces vaccine antigen specific cell mediated immunity.</description><subject>Adjuvants, Immunologic</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>Cellular immunity</subject><subject>Cervical cancer</subject><subject>Cervical intraepithelial neoplasia</subject><subject>Cervical Intraepithelial Neoplasia - immunology</subject><subject>Cervical Intraepithelial Neoplasia - therapy</subject><subject>Cervical Intraepithelial Neoplasia - virology</subject><subject>Cholesterol - therapeutic use</subject><subject>Delayed type hypersensitivity</subject><subject>Drug Combinations</subject><subject>Experimental design</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Histology</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Hypersensitivity</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Immunotherapy</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Lymphocytes</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Oncogene Proteins, Viral - genetics</subject><subject>Papillomaviridae - immunology</subject><subject>Papillomavirus E7 Proteins</subject><subject>Papillomavirus Infections - immunology</subject><subject>Papillomavirus Infections - therapy</subject><subject>Papillomavirus Infections - virology</subject><subject>Patients</subject><subject>Phospholipids - therapeutic use</subject><subject>Proteins</subject><subject>Recombinant Fusion Proteins - immunology</subject><subject>Recombinant Fusion Proteins - therapeutic use</subject><subject>Repressor Proteins - genetics</subject><subject>Saponins - therapeutic use</subject><subject>Tumors</subject><subject>Uterine Cervical Dysplasia - immunology</subject><subject>Uterine Cervical Dysplasia - therapy</subject><subject>Uterine Cervical Dysplasia - virology</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Viral load</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkdGK1DAUhoMo7jj6CEpA9K41aZO0uZJlGN2BlV10kL0LaXrKpLRpTdpZ5t4n8BF8NJ_ELFNY8Mark5zzncM5_4_Qa0pSSqj40KZHbYx1kGaEsJTwlND8CVrRssiTjNPyKVqRTLCEUXJ3gV6E0BJCeE7lc3RBeXyQnK3Qr9uDDoApDtNcn_DQ4Kvb71QkYQRjG2uw7fvZDdMBvB5P-N5OB7wV2wI3c7CDw6MfJrAOa1fj3bfNzZfL_dfd3Z-fv7Gu2_mo3YRj9X7owZ2bDfijNbqL6clrGGMOOhv_Doax08Hql-hZo7sAr5a4RvtP2_3mKrm--bzbXF4nhlE5JbKsQGRVJnIicsgZFazIaMUrRmvJjYwh1nMjoeJ5U9eESdJAXUqaaZ6V-Rq9P4-NJ_yYIUyqt8FA1-m4yRyUKAiXTBQRfPsP2A6zd3E1FXWURBAe5VwjfqaMH0Lw0KjR2177k6JEPTimWrU4ph4cU4Sr6Fjse7NMn6se6seuxaIIvFsAHaJujdfO2PDICUYpZTJyH88cRM2OFrwKxoIzUFsPZlL1YP-zyl9Llrc-</recordid><startdate>20041125</startdate><enddate>20041125</enddate><creator>Frazer, Ian H.</creator><creator>Quinn, Michael</creator><creator>Nicklin, Jim L.</creator><creator>Tan, Jeffrey</creator><creator>Perrin, Lew C.</creator><creator>Ng, Peng</creator><creator>O’Connor, Vivienne M.</creator><creator>White, Olivia</creator><creator>Wendt, Ngaire</creator><creator>Martin, Juliet</creator><creator>Crowley, Jayne M.</creator><creator>Edwards, Stirling J.</creator><creator>McKenzie, Andrew W.</creator><creator>Mitchell, Susan V.</creator><creator>Maher, Darryl W.</creator><creator>Pearse, Martin J.</creator><creator>Basser, Russell L.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20041125</creationdate><title>Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia</title><author>Frazer, Ian H. ; Quinn, Michael ; Nicklin, Jim L. ; Tan, Jeffrey ; Perrin, Lew C. ; Ng, Peng ; O’Connor, Vivienne M. ; White, Olivia ; Wendt, Ngaire ; Martin, Juliet ; Crowley, Jayne M. ; Edwards, Stirling J. ; McKenzie, Andrew W. ; Mitchell, Susan V. ; Maher, Darryl W. ; Pearse, Martin J. ; Basser, Russell L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-98be62b263063e34164721b5b41d95c941de623c9eb53fdd0490fed8912a5283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjuvants, Immunologic</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>Cellular immunity</topic><topic>Cervical cancer</topic><topic>Cervical intraepithelial neoplasia</topic><topic>Cervical Intraepithelial Neoplasia - immunology</topic><topic>Cervical Intraepithelial Neoplasia - therapy</topic><topic>Cervical Intraepithelial Neoplasia - virology</topic><topic>Cholesterol - therapeutic use</topic><topic>Delayed type hypersensitivity</topic><topic>Drug Combinations</topic><topic>Experimental design</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Histology</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Hypersensitivity</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Immunotherapy</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Lymphocytes</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Oncogene Proteins, Viral - genetics</topic><topic>Papillomaviridae - immunology</topic><topic>Papillomavirus E7 Proteins</topic><topic>Papillomavirus Infections - immunology</topic><topic>Papillomavirus Infections - therapy</topic><topic>Papillomavirus Infections - virology</topic><topic>Patients</topic><topic>Phospholipids - therapeutic use</topic><topic>Proteins</topic><topic>Recombinant Fusion Proteins - immunology</topic><topic>Recombinant Fusion Proteins - therapeutic use</topic><topic>Repressor Proteins - genetics</topic><topic>Saponins - therapeutic use</topic><topic>Tumors</topic><topic>Uterine Cervical Dysplasia - immunology</topic><topic>Uterine Cervical Dysplasia - therapy</topic><topic>Uterine Cervical Dysplasia - virology</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Viral load</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frazer, Ian H.</creatorcontrib><creatorcontrib>Quinn, Michael</creatorcontrib><creatorcontrib>Nicklin, Jim L.</creatorcontrib><creatorcontrib>Tan, Jeffrey</creatorcontrib><creatorcontrib>Perrin, Lew C.</creatorcontrib><creatorcontrib>Ng, Peng</creatorcontrib><creatorcontrib>O’Connor, Vivienne M.</creatorcontrib><creatorcontrib>White, Olivia</creatorcontrib><creatorcontrib>Wendt, Ngaire</creatorcontrib><creatorcontrib>Martin, Juliet</creatorcontrib><creatorcontrib>Crowley, Jayne M.</creatorcontrib><creatorcontrib>Edwards, Stirling J.</creatorcontrib><creatorcontrib>McKenzie, Andrew W.</creatorcontrib><creatorcontrib>Mitchell, Susan V.</creatorcontrib><creatorcontrib>Maher, Darryl W.</creatorcontrib><creatorcontrib>Pearse, Martin J.</creatorcontrib><creatorcontrib>Basser, Russell L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frazer, Ian H.</au><au>Quinn, Michael</au><au>Nicklin, Jim L.</au><au>Tan, Jeffrey</au><au>Perrin, Lew C.</au><au>Ng, Peng</au><au>O’Connor, Vivienne M.</au><au>White, Olivia</au><au>Wendt, Ngaire</au><au>Martin, Juliet</au><au>Crowley, Jayne M.</au><au>Edwards, Stirling J.</au><au>McKenzie, Andrew W.</au><au>Mitchell, Susan V.</au><au>Maher, Darryl W.</au><au>Pearse, Martin J.</au><au>Basser, Russell L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2004-11-25</date><risdate>2004</risdate><volume>23</volume><issue>2</issue><spage>172</spage><epage>181</epage><pages>172-181</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>: Persistent infection of cervical epithelium with “high risk” human papillomavirus (HPV) results in cervical intraepithelial neoplasia (CIN) from which squamous cancer of the cervix can arise. A study was undertaken to evaluate the safety and immunogenicity of an HPV16 immunotherapeutic consisting of a mixture of HPV16 E6E7 fusion protein and ISCOMATRIX™ adjuvant (HPV16 Immunotherapeutic) for patients with CIN.
: Patients with CIN (
n = 31) were recruited to a randomised blinded placebo controlled dose ranging study of immunotherapy.
: Immunotherapy was well tolerated. Immunised subjects developed HPV16 E6E7 specific immunity. Antibody, delayed type hypersensitivity, in vitro cytokine release, and CD8 T cell responses to E6 and E7 proteins were each significantly greater in the immunised subjects than in placebo recipients. Loss of HPV16 DNA from the cervix was observed in some vaccine and placebo recipients.
: The HPV16 Immunotherapeutic comprising HPV16E6E7 fusion protein and ISCOMATRIX™ adjuvant is safe and induces vaccine antigen specific cell mediated immunity.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15531034</pmid><doi>10.1016/j.vaccine.2004.05.013</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2004-11, Vol.23 (2), p.172-181 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67059467 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adjuvants, Immunologic Adolescent Adult Applied microbiology Biological and medical sciences Cancer Vaccines - immunology Cancer Vaccines - therapeutic use Cellular immunity Cervical cancer Cervical intraepithelial neoplasia Cervical Intraepithelial Neoplasia - immunology Cervical Intraepithelial Neoplasia - therapy Cervical Intraepithelial Neoplasia - virology Cholesterol - therapeutic use Delayed type hypersensitivity Drug Combinations Experimental design Female Fundamental and applied biological sciences. Psychology Histology Human papillomavirus Humans Hypersensitivity Immunization Immunogenicity Immunotherapy Infections Laboratories Lymphocytes Medical sciences Microbiology Middle Aged Miscellaneous Oncogene Proteins, Viral - genetics Papillomaviridae - immunology Papillomavirus E7 Proteins Papillomavirus Infections - immunology Papillomavirus Infections - therapy Papillomavirus Infections - virology Patients Phospholipids - therapeutic use Proteins Recombinant Fusion Proteins - immunology Recombinant Fusion Proteins - therapeutic use Repressor Proteins - genetics Saponins - therapeutic use Tumors Uterine Cervical Dysplasia - immunology Uterine Cervical Dysplasia - therapy Uterine Cervical Dysplasia - virology Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral load Virology |
| title | Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX™ adjuvant in women with cervical intraepithelial neoplasia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T01%3A12%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%201%20study%20of%20HPV16-specific%20immunotherapy%20with%20E6E7%20fusion%20protein%20and%20ISCOMATRIX%E2%84%A2%20adjuvant%20in%20women%20with%20cervical%20intraepithelial%20neoplasia&rft.jtitle=Vaccine&rft.au=Frazer,%20Ian%20H.&rft.date=2004-11-25&rft.volume=23&rft.issue=2&rft.spage=172&rft.epage=181&rft.pages=172-181&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2004.05.013&rft_dat=%3Cproquest_cross%3E67059467%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559060555&rft_id=info:pmid/15531034&rft_els_id=S0264410X04004189&rfr_iscdi=true |